Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.62 ^DKK	+1.85%		+5.08%	-8.82%

Feb. 29	Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Cessatech A/S Appoints Martin Olin as the Chairman of the Board

March 23, 2023 at 09:00 am EDT

Cessatech A/S announces that the Board of Directors has appointed Martin Olin as the Chairman of the Board. Martin Olin is CEO of BerGenBio and has been on the Board of Cessatech since August 2020. His biotech experience and knowledge of the company will be important as Cessatech moves into the next development for CT001.

The previous Chairman of the Board, Adam Steensberg will continue as Board member of Cessatech. Martin Olin will be allocated additional 20,000 incentive warrants (in total 65,000) to the same level as previously allocated to the Chairman of the Board from the January 2023 allocation. Incentive warrant terms are the same as previously announced 17 January 2023.

Latest news about Cessatech A/S

Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	23-10-25	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	23-09-21	CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	23-09-12	MT
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	23-09-12	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Cessatech A/S Secures DKK 5 Million Loan Facility Agreement to Support the US Launch of its Lead Program CT001	23-08-17	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	23-06-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-29	CI
Cessatech A/S Appoints Martin Olin as the Chairman of the Board	23-03-23	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Cessatech A/S Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Cessatech to Raise $2 Million in Rights Offer	22-11-14	MT
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	22-09-23	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	22-09-05	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	22-06-30	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	22-05-16	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Cessatech A/S Announces Board Changes	22-03-17	CI
Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001	22-03-08	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-24	CI

Chart Cessatech A/S

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data